CS210041B1 - Preparation for healing the skin diseaes - Google Patents
Preparation for healing the skin diseaes Download PDFInfo
- Publication number
- CS210041B1 CS210041B1 CS641279A CS641279A CS210041B1 CS 210041 B1 CS210041 B1 CS 210041B1 CS 641279 A CS641279 A CS 641279A CS 641279 A CS641279 A CS 641279A CS 210041 B1 CS210041 B1 CS 210041B1
- Authority
- CS
- Czechoslovakia
- Prior art keywords
- copper
- treatment
- monojodoctane
- whole body
- vulgaris
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title description 6
- 241000045500 Diseae Species 0.000 title 1
- 230000035876 healing Effects 0.000 title 1
- 239000010949 copper Substances 0.000 claims description 16
- 238000011282 treatment Methods 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 15
- -1 monoiodoctane monohydrate Chemical compound 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 6
- 206010040943 Skin Ulcer Diseases 0.000 claims description 6
- 238000001816 cooling Methods 0.000 claims description 6
- 229910052802 copper Inorganic materials 0.000 claims description 6
- 230000000813 microbial effect Effects 0.000 claims description 6
- 238000012360 testing method Methods 0.000 claims description 5
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 4
- 206010000496 acne Diseases 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 208000017520 skin disease Diseases 0.000 claims description 4
- 206010021531 Impetigo Diseases 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 230000004807 localization Effects 0.000 claims description 3
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 208000003251 Pruritus Diseases 0.000 claims description 2
- VEQOALNAAJBPNY-UHFFFAOYSA-N antipyrine Chemical compound CN1C(C)=CC(=O)N1C1=CC=CC=C1 VEQOALNAAJBPNY-UHFFFAOYSA-N 0.000 claims description 2
- 238000003745 diagnosis Methods 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 230000007803 itching Effects 0.000 claims description 2
- 230000008961 swelling Effects 0.000 claims description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 206010012468 Dermatitis herpetiformis Diseases 0.000 claims 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000000460 chlorine Chemical group 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 238000011835 investigation Methods 0.000 claims 1
- 229910052740 iodine Chemical group 0.000 claims 1
- 239000011630 iodine Chemical group 0.000 claims 1
- 206010040882 skin lesion Diseases 0.000 claims 1
- 231100000444 skin lesion Toxicity 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 238000005303 weighing Methods 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 description 6
- 208000026935 allergic disease Diseases 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 206010063409 Acarodermatitis Diseases 0.000 description 5
- 208000007163 Dermatomycoses Diseases 0.000 description 5
- 241000447727 Scabies Species 0.000 description 5
- 239000002674 ointment Substances 0.000 description 5
- 208000005687 scabies Diseases 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 208000006311 Pyoderma Diseases 0.000 description 4
- 201000003929 dermatomycosis Diseases 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 3
- 230000009610 hypersensitivity Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 230000005291 magnetic effect Effects 0.000 description 3
- 239000003883 ointment base Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- DDUHZTYCFQRHIY-UHFFFAOYSA-N 7-chloro-3',4,6-trimethoxy-5'-methylspiro[1-benzofuran-2,4'-cyclohex-2-ene]-1',3-dione Chemical compound COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 description 2
- 241001480043 Arthrodermataceae Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- QBSGXIBYUQJHMJ-UHFFFAOYSA-N bromochlorosalicylanilide Chemical compound OC1=CC=C(Br)C=C1C(=O)NC1=CC=C(Cl)C=C1 QBSGXIBYUQJHMJ-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000037304 dermatophytes Effects 0.000 description 2
- 229910052949 galena Inorganic materials 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical compound OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 description 2
- XCAUINMIESBTBL-UHFFFAOYSA-N lead(ii) sulfide Chemical compound [Pb]=S XCAUINMIESBTBL-UHFFFAOYSA-N 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- IHZIQQBUAKZVCI-XTANLHRZSA-N 1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole;(8s,9s,10r,11s,13s,14s,17r)-11,17-dihydroxy-10,13-dimethyl-17-[2-(4-methylpiperazin-1-yl)acetyl]-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-3-one;nitric acid;hydrochl Chemical compound Cl.O[N+]([O-])=O.ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1.C1CN(C)CCN1CC(=O)[C@]1(O)[C@@]2(C)C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2CC1 IHZIQQBUAKZVCI-XTANLHRZSA-N 0.000 description 1
- OCVXSFKKWXMYPF-UHFFFAOYSA-N 2-chloroimidazole Chemical compound ClC1=NC=CN1 OCVXSFKKWXMYPF-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- RLFWWDJHLFCNIJ-UHFFFAOYSA-N Aminoantipyrine Natural products CN1C(C)=C(N)C(=O)N1C1=CC=CC=C1 RLFWWDJHLFCNIJ-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241001602958 Ceresium Species 0.000 description 1
- IIUZTXTZRGLYTI-UHFFFAOYSA-N Dihydrogriseofulvin Natural products COC1CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 IIUZTXTZRGLYTI-UHFFFAOYSA-N 0.000 description 1
- 241001480035 Epidermophyton Species 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- UXWOXTQWVMFRSE-UHFFFAOYSA-N Griseoviridin Natural products O=C1OC(C)CC=C(C(NCC=CC=CC(O)CC(O)C2)=O)SCC1NC(=O)C1=COC2=N1 UXWOXTQWVMFRSE-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 206010024438 Lichenification Diseases 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- 241000893976 Nannizzia gypsea Species 0.000 description 1
- 241001310793 Podium Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 241000223238 Trichophyton Species 0.000 description 1
- 241001045770 Trichophyton mentagrophytes Species 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- YMCOHQVWOBMDCZ-UHFFFAOYSA-L Zinc undecylenate Chemical compound [Zn+2].[O-]C(=O)CCCCCCCCC=C.[O-]C(=O)CCCCCCCCC=C YMCOHQVWOBMDCZ-UHFFFAOYSA-L 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 1
- 239000006161 blood agar Substances 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000007765 cera alba Substances 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 150000001879 copper Chemical class 0.000 description 1
- 229940116318 copper carbonate Drugs 0.000 description 1
- GEZOTWYUIKXWOA-UHFFFAOYSA-L copper;carbonate Chemical compound [Cu+2].[O-]C([O-])=O GEZOTWYUIKXWOA-UHFFFAOYSA-L 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 description 1
- 229960002867 griseofulvin Drugs 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 229960005222 phenazone Drugs 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940045860 white wax Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Description
Československa socialistická
REPUBLIKA ( 19 )
POPIS VYNÁLEZU
K AUTORSKÉMU OSVĚDČENI U 210041 (Π) (ΒΪ)
/22/ Přihlášené 24 09 79/21/ /PV 6412-79/ (51) lnt Cl? A 61 K 31/30//C 07 F 1/08 (40) Zverejnené 31 12 80
ÚŘAD PRO VYNÁLEZY
A OBJEVY (45) Vydané 15 07 8 2 (75)
Autor vynálezu MĚLNÍK MILAN RNDr. CSc., MARŤANOVA HELENA MUDr.
a KAPALA JÚLIHS RNDr., BRATISLAVA (54) Prípravok na liečenie kožných onemocnění i
Vynález sa týká přípravku na liečeniekožných onemocnění v humánnej medicíně naj-ma: Pyodermie - Xmpetigo vulgaris, Dermato-mykozy, Scabies a v menšej miere na Acnevulgaris, Ulcus cruris a Exseaia microbiále.
Pri liečbe Pyodermie - Impetigo vulgarispri celkovej í lokálnej sa používajú anti-biotika: chloramphenícol ung., tetracyklinung. a framykoín ung. Okrem antibiotik sapoužívaju aj sulfonamidy. Nevýhody vyššiespomínaných líečivých prípravkov je vyvolá-vanie alergizácii a rezistenciu daných mi-kroorganizmov.
Pri liečbe celkovej dermatomykozy sa po-užívajú gricín /griseofulvin//NDR/, ktorýmá tiež nežíadúce vedlajšie účinky, vyvolá-vá okrem iných aj neurologické a alergicképrejavy. Pri lokálnej dermatomykoze sa po-užívá sálifungin /5-bromsalicyl-4-chlorani~lidům 0,5 g, triaetylglycol q. s. v 25 mlroztoku/ /Galena/; mykoseptin /acidum unde-cylenícum 5 g, zíncunt undecylanícum 20 gv 100 g mastí/ /Léčiva/; myco-polycid krém/ chlor imidazo 1 hydrochlor icuni 5 %/ /Grunen-thal, NSR/; mycosolon ung. /21-/desoxy-N--methyl~N"-piperazinyl/-prednisolonum hydro-chloricum 0,25 miconazolum 2 % v masto-vom základe/ /Richter, MLR/ a iné. Nevýhody,niektoré z nich vyvolávajú přecitlivělost,iritačne dermatitis, níekedy erytém a pod.
Acne vulgaris, pri liečbe tohto onemocne-nia prakticky neexistuje preparát, ktorý bynevyvolával dráždivost. Vačšinou sa používa-jú přípravky ako pri liečbe pyodermie /naj-ma hydrokortizonové masti s přísadami anti-bakteriáínymi, alebo anti biotikami/.
Pri liečbe Ulcus cruris - pri hodné zne- 2 čištěných spodin vredov - Lavage /obklady/,pri arabulantných ošetreniach nevhodné.
Okrem toho sa často aplíkuj^ú antibiotickémasti, ktorých nevýhodou je, Že po dlhšompoužívaní vyvolávajú přecitlivělost a rezí-steneiu.
Scabies - na jeho liečbu sa používá Sca-bitol /phenylum salicylicum 4,6 g, benzylumbenzoicum 9,2 g v 100 ml roztoku/ /Galena/,Scabilan a pod. Nevýhody - vyvolávajú pře-citlivělost.
Exséma microbiále - ide o alergické o-chorenie. Aplikujú sa najčastejšie antibio-tické masti, masti z rady sulfonamidov.Nevýhody - alergízácíe. PIX pasty - nevý-hodné pre zápach, farbivost a dráždivostpokožky.
Podstátou vynálezu je prípravok na liecenie kožných onemocnění, kde účinnou látkouje monohalogénoctan meďnatý vzorca CU/XCH2COO/2» kde X znamená fluór, chlór,bróm, alebo jód, alebo jeho hydrát, alebo'adukt s 1-fenyl-2,3~dimetyl-5-pyrazolom/antipyrin/ a mastový základ.
Monojódoctan mednatý, zloženiaCu/ICH2COO/2, bol připravený /M. Mělník,Acta Chem. Scand., 25 /1971/1977/, reakciouzásaditého uhličitanu meďnatého a koncen-trovaného vodného roztoku kyseliny mono-jódoctovej v molárnom pomere 1:2 v prospěchkyseliny. Vzniknutý raodro-zelený produkt,bol filtráciou oddělený, na filtri premý-vaný destilovanou vodou a volné sušený navzduchu.
Zloženie izolovaného produktu sa určil .na základe výsledkov analýzy médi, uhlíkaa vodíka. Rozborom infračervených spektier 210041 210041 3 4 v Nujol suspenzii meraných, sa zistili, žeobidva atomy kyslíka karboxylových skupinsa viažu systémom syn,-syn na atomy médi.Spektra elektrónovej paramagnetícke.j rezo-nancie, merané pri laboratornej tep.lote,sú typické pre komplexy Cu/II/ s hodnotouefektívneho spinu, S s 1. Elektronové spek-tra tohto komplexu, merané taktiež v Nujolsuspenzii, vykazovali dva charakteristicképásy, odpovedajuce přítomnosti dvojjadro-vých molekúl v štruktúre tohto komplexu, Z hlediska magnetického, patří tento kom-plex roedzi magneticky nezriedené raednatékomplexy. Priebeh magnetickej susceptibili-ty v závislosti na teplote, je velmi cha-rakteristický pre komplex s dvojjadrovoustrukturou.
Na základe výsledkov spektier a magnetic-kých meraní sa usudzuje, že monojódoctanmednatý je dvojjadrovej struktury typu oc~tanu mednatého /J. N. van Niekerk a F. R. L. Schoening, Acta Crystallogr . , 6 /1953/227/.
Ostatně zlúčeniny všeobecného vzorcaCu/XCH2C00i2l, kde X znamená fluór, chlór,bróm, alebo jód a L znamená vodu, alebo1-fenyl-2,3~dimety1-5-pyrazulon; bolí při-pravené analogicky ako monojódoctan medna-tý /K. S. Patel a J. A. Faniran, J. Inorg.Nucl. Chem., 39 /1977/ 1149; M. Mělník, Fínn. Chem. Lett,, / 1 97 4/ 14.2 a lit. tamcitovaná/.
Adukty s 1-fenyl-2,3-dimetyl-5-pyrazo-lonora bol připravený reakciou základnýchkomplexov zloženia CU/XCH2COO/2 s l-fenyi--2,3-dimety1-5-pyrazolom v prostředí meta-nolu v molárnom pomere 1:1 /11. Mělník,
Finn. Chem. Lett., /1974/ 142/.
Spektrálné a magnetické vlastností tých-to aduktov sú analogické monojódoctanu meď-natému, čo dovoluje predpokladač analogickéstrukturu typu octanu mednatého.
Tento prípravok je možno aplikovať am-bulantně, nie je riziko alergizácie, rezi-stencie, nezapáchá, nedráždi, nefarbí, jed-noduchá příprava a v neposlednom radě eko-nomicky výhodné.
Masťové základy sú rožne, vybrali sa:Ambiderman /η. p. Léčiva, Praha/ zloženia: metylparaben 0,20 g propylparaben 0,05 g tekutý parafín 31,50 g izopropylpalmitát 8,00 g bíely vosk 8,00 g cetylalkohol 3,00 g solvasol.O 100 Z 4,00 g polynol A 1,00 g propylenglykol dest. 5,00 g carbopol 940 0,10 g trietanolamín 0,73 g dimeneralizovaná voda ster. 32,02 g
Synderman CH /n. p. Léčiva, Praha/ zloženia:
Alcoholia lanae 6,00 g cerajaponica 0,50 g cera alba 1,00 g ^Mon C /glycerylmonostearan/ 0,50 g ceresíum 8,00 g parafťinum solidům 6,00 g paraffinum liquídum 36,00 g metylparabenum 0,20 g tocoferylium aceticum 100 % 0,02 g vaselinum flavuia 41,78 g
Protegin /výrobok Th. Goldschmidt AG, NSR/zloženia: 1 Z kyselina boritá, kyselina citrónová akyselina octová, 1 Z cholesterin 1 7, gáfor 20 7. síry 3 7. tanin 10 7. oxichlorid bi smuti tý 10 7. oxid zinočnatý
Komplexně zlúčeniny všeobecného vzorcaCu/XCH2C00/2, kde X znamená fluor, chlór,bróm, alebo jód, ako aj ich adukty s vodou,či 1-fenyl“2,3-diraetyl-5-pyrazolom, bolískúŠané na baktériach týchto druhov:Staphylococcus aureus MAV 43/60, Escheri-chia coli 324/70 a Pseudomonas aeruginosa79/70. Antiťungálna aktivita zasa na:'Trichophyton mantagrophytes var. interdi-gitale, Trichophyton mentagrophytes var.granulosa, Microsporum gypseum a Epider-mophyton floccosuin.
Stanovenie minimálnej inhibičnej končen-trácie /MIC/ sa robilo v tekutom médiu, preStaphylococcus aureus v Mueller-Hintonovombujóne /výrc-bca Imuna, Sarišské Michalany/.Pre Escherichia coli rainimálnu pódu zlože-nia: /L. Drobnica, Habilitačná práca, CHTF,SVŠT, Bratislava, 1962/ k2hpo4KH2PO4 citran sodnýMgSO4 . 7H20močovinagluko zadest. voda
Pre Pseudomonas aeruginosu minimálnupódu podlá /Eagon, R. G. a P. V. Philbs,'Can. J. Biochem., 49 /1971/ 103/, zloženia; glukóza 5,4 g K2HP04 7,0 g KH2P04 3,0 g /NH4/2S04 0,9 g
MgSO4 resp. MgS04 . 7H2O 0,6 g resp. 1,2 g pH » 7 7 g3 g0,5 g0, 1 g" 0,45 g \,0 g1 000 craJ.
Pri testovaní antimíkrobiálneho účinkusa použila suspenzia o hustotě 10®/ml mikro-biálnych jedincov. Suspenzia sa připravilaz 20 hodinových kultúr v příslušných živ-ných roztokoch. Pracovalo sa s koncentrá-ciou Cu/II/ komplexov 100, 250, 500 a1 000 ^ug/ral. Uvedené množstvo komplexu sarozpustilo v 0,01 ml dimety1sulfoxidu a popřidaní prísluŠnej živnej pódy přidalabakteriálna suspenzia v množstve 0,1 ml.Inkubácia prebiehala v termostate 48 hodpri teplote 37 °C. Po inkubácii vzorky bolivyočkované na pevné pódu /krvný agar/ a po24 hod odčítali sa výsledky. Odčítáním ras-tu, alebo zábrany sa takto zistil koeficientinhibície.
Dermatofyty sa kultivovali na šikmomSabourandovom agare /výrobca Imuna, Paříž-ské Michalany/ 21 dní. Pri testovaní sa po-užili tie ísté koncentrácie ako pri bakté-riach. Inkubácia prebiehala pri izbovejteplote /18-22 °C/. OdČítanie rastu resp.koeficientu inhibície sa robili po 7, 14a 21 dňoch. Každý pokus sa doplnil kontrol-ným testora. MIC pre testované komplexy Cu/II/ saznižovala v radě Cu/lCH2COO/2 >Cu/BrCH2COO/2> Cu/ClCH2COO/2>Cu/FCH2COO/2. V případemonojódoctanu mednatého bola najvýraznej“šia a pohybovala sa okolo 100 ^ug/ml. Jezaujímavé, že hydráty, ako aj ich aduktys 1-fenyl-2,3-dimetyl-5-pyrazolom, vykazo-vali prakticky tie isté hodnoty MIC.
Prje testovanie v humánnej medicíně, bolvybraný monojódoctan mednatý, ktorý vykazo-val v laboratórnych skúškach na spomínanébaktérie, ako aj dermatofyty, najvyšší ú-,činok. V humánnej medicíně boli robené kli-
Claims (3)
1. Prípravok na liečenie kožných onemoc-nění vyznačujúci sa tým, že pozostávaz raastového základu a ako účinnú látku ob-sahuje komplexnú zlúčeninu monohalogénoc-tan meďnatý vzorca - Cu/XCH2COO/2 kde X znamená fluór, chlor, bróm, alebo jód; VYNÁLEZU alebo jeho hydrát, alebo adukt s 1-fenyl-•2,3-dimetyl-5~pyrazolonom.
2. Prípravok na liečenie kožných onemocnení podlá bodu 1, vyznačujúci sa tým, žekoncentráeia účinnej látky v přípravku je0,5 až
3 Z. SevprografÍa. η. p·. rivod 7. Moet
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CS641279A CS210041B1 (en) | 1979-09-24 | 1979-09-24 | Preparation for healing the skin diseaes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CS641279A CS210041B1 (en) | 1979-09-24 | 1979-09-24 | Preparation for healing the skin diseaes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CS210041B1 true CS210041B1 (en) | 1982-01-29 |
Family
ID=5411092
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CS641279A CS210041B1 (en) | 1979-09-24 | 1979-09-24 | Preparation for healing the skin diseaes |
Country Status (1)
| Country | Link |
|---|---|
| CS (1) | CS210041B1 (cs) |
-
1979
- 1979-09-24 CS CS641279A patent/CS210041B1/cs unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69312870T2 (de) | Salze der CIS und Trans-Traumatinsäure mit wundheilender sowie bacteriostatischer, antiviraler, antibiotischer oder fungizider Wirkung | |
| Dharmawati et al. | Antibacterial activity of Lumbricus rubellus earthworm extract against Porphyromonas gingivalis as the bacterial cause of periodontitis | |
| AU2010308741B2 (en) | A skin external composition comprising a salt and sugar as active ingredients for preventing and treating vaginosis and the use thereof | |
| EP2258705B1 (en) | Pharmaceutically acceptable salts of anti-infective quinolone compound | |
| Li et al. | Antibacterial activity of a scorpion-derived peptide and its derivatives in vitro and in vivo | |
| DE2140719A1 (de) | Arzneimittel auf der Grundlage eines Pyrazolons | |
| CS210041B1 (en) | Preparation for healing the skin diseaes | |
| WO2019225786A1 (ko) | 정향, 히비스커스, 및 코코넛 추출물을 유효성분으로 포함하는 항균 및 항진균 조성물 | |
| CN107213142A (zh) | 氧化白藜芦醇或氧化白藜芦醇联合抗生素在制备抗真菌感染产品中的应用 | |
| Zhang et al. | Synthesis and evaluation of sulfonyl-substituted ruthenium complex as potential antibacterial activity against Staphylococcus aureus | |
| RU2136668C1 (ru) | N,n'-(сульфонилди-1,4-фенилен)бис(n'',n''- диметилформамидин)1,2,3,4-тетрагидро-6-метил-2,4- диоксо-5-пиримидинсульфонат, стимулирующий клеточный метаболизм и обладающий иммунотропной и антимикобактериальной активностью | |
| CN118121581A (zh) | 一种萜类化合物在防治奶牛乳腺炎致病菌中的用途 | |
| Symonds et al. | The penetration of ofloxacin into bronchial secretions | |
| JP7551752B2 (ja) | 慢性創傷治癒組成物およびその適用 | |
| RU2326667C1 (ru) | Средство для лечения гнойно-воспалительных заболеваний кожи и мягких тканей различной этиологии | |
| CN115737647A (zh) | 血根碱或其盐在抑制伪中间型葡萄球菌中的应用 | |
| da Fonseca Orcina et al. | Antibacterial and antifungal activity of intraoral products containing phthalocyanine: in vitro study | |
| CN105168360A (zh) | 一种治疗痤疮、粉刺的植物提取物复方擦剂及其制备方法 | |
| Bayed et al. | Susceptibility pattern in pathogenic bacteria isolated from clinical specimens of wounds antimicrobial effects of camel’surfline compared with antibiotic | |
| RU2794967C1 (ru) | Способ лечения домашних животных при маститах | |
| CN119792466B (zh) | 一种具有抑菌去屑止痒功效的头皮护理组合物及其制备方法和应用 | |
| Shamsi et al. | In-Vitro antioxidant, antibacterial and anti-inflammatory characterization of Indian honey | |
| RO127465A2 (ro) | Complecşi metalici ai clorhexidinei şi procedeu de obţinere a acestora | |
| AU2021209256B2 (en) | Herbal formulations of carnivorous plants and methods for treating inflammation | |
| US20140017340A1 (en) | Skin external composition comprising a pure salt and sugar as active ingredients for preventing and treating vaginosis and the use thereof |